Key result
Clonal hematopoiesis features interact with traditional cardiovascular risk factors to influence ischemic events.
Why the study?
Clonal hematopoiesis encompasses diverse somatic mutations with cardiovascular implications, warranting characterization of the spectrum of patients referred to cardiology.
Understanding the clinical context and genetic features of clonal hematopoiesis can guide individualized cardiovascular risk assessment and preventive strategies.
No takes yet. Share an insight, caveat, or question.
Informs individualized cardiovascular risk mitigation when clonal hematopoiesis is identified; extends literature by contextualizing genotype, detection setting, and clinical history.
Clonal hematopoiesis encompasses diverse somatic mutations in hematopoietic cells, ranging from age-related expansions to mutations acquired after cytotoxic therapy, with implications for hematologic malignancy and cardiovascular disease. We characterize the spectrum of patients referred to cardiology for clonal hematopoiesis, including incidental detection during cytopenia or cancer predisposition workup, coexisting malignancy, and posttherapy surveillance. High-risk features, large clone size, multiple mutations, and specific driver genes interact with traditional cardiovascular risk factors to influence ischemic events. Contextualizing clonal hematopoiesis by detection setting, genotype, and clinical history informs individualized cardiovascular evaluation and risk mitigation, guiding mechanistically targeted preventive strategies and trial design.
Oren et al. (2026) studied this question. Clonal hematopoiesis features, including large clone size and multiple mutations, interact with traditional cardiovascular risk factors to influence ischemic events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: